Cell Expansion Market Size, Share & Trends Analysis Report By Product (Instruments, Culture Flasks & Accessories, Consumables), By Cell Type (Mammalian, Microbial), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Cell Expansion Market Size, Share & Trends Analysis Report By Product (Instruments, Culture Flasks & Accessories, Consumables), By Cell Type (Mammalian, Microbial), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Cell Expansion Market Growth & Trends

The global cell expansion market size is expected to reach USD 47.13 billion by 2030 registering a CAGR of 12.85%, according to a new report by Grand View Research, Inc. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies. Therefore, significant developments in cord blood SCs expansion technologies are expected to boost market growth.

Companies have made heavy investments for the expansion of tissue-engineered products and the development of biologics. For instance, in March 2019, Merck KGaA invested USD 168 million for the expansion of its biologics manufacturing facility in Switzerland. Such initiatives are expected to boost the demand for solutions required for biologic development, thereby leading to market growth.

Bioreactors are fundamental tools in this market. Extensive research studies related to the applications of bioreactor engineering approaches have led to the incorporation of novel culture technologies. Moreover, the combined use of automated bioreactors with the microcarrier technology leads to an efficient expansion and enrichment of the cancer SCs. As a result, these approaches have gained immense traction in this market.

Cell Expansion Market Report Highlights

• Broad portfolio of automated expansion systems along with improvements in bioreactor design for large-scale bioproduction results in the lucrative growth opportunity for instruments
• The microbial cells segment is expected to witness the fastest growth rate owing to the implementation of high-throughput cultivation approaches and techniques that avoid the formation of biofilms
• Biopharmaceuticals segment held the largest revenue share in 2022 due to growth in the demand for biosimilars, continuous R&D investments in biomanufacturing, and rise in the number of approvals for biologics
• Asia Pacific is expected to witness the fastest CAGR from 2023 to 2030 due to presence of several consortiums that focus on the evolving fields in the biomedical industry

Please note The report will be delivered in 2-3 business days upon order notification.